@article {Fahed19013086, author = {Akl C. Fahed and Minxian Wang and Julian R. Homburger and Aniruddh P. Patel and Alexander G. Bick and Cynthia L. Neben and Carmen Lai and Deanna Brockman and Anthony Philippakis and Patrick T. Ellinor and Christopher A. Cassa and Matthew Lebo and Kenney Ng and Eric S. Lander and Alicia Y. Zhou and Sekar Kathiresan and Amit V. Khera}, title = {Polygenic background modifies penetrance of monogenic variants conferring risk for coronary artery disease, breast cancer, or colorectal cancer}, elocation-id = {19013086}, year = {2019}, doi = {10.1101/19013086}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Genetic variation can predispose to disease both through (i) monogenic risk variants in specific genes that disrupt a specific physiologic pathway and have a large effect on disease risk and (ii) polygenic risk that involves large numbers of variants of small effect that affect many different pathways. Few studies have explored the interaction between monogenic risk variants and polygenic risk.Methods We identified monogenic risk variants and calculated polygenic scores for three diseases, coronary artery disease, breast cancer, and colorectal cancer, in three study populations {\textemdash} case-control cohorts for coronary artery disease (UK Biobank; N=12,879) and breast cancer (Color Genomics; N=19,264), and an independent cohort of 49,738 additional UK Biobank participants.Results In the coronary artery disease case-control cohort, increased risk for carriers of a monogenic variant ranged from 1.3-fold for those in the lowest polygenic score quintile to 12.6-fold for those in the highest. For breast cancer, increased risk ranged from 2.4 to 6.9-fold across polygenic score quintiles. Among the 49,738 UK Biobank participants who carried a monogenic risk variant, the probability of disease at age 75 years was strongly modified by polygenic risk. Across individuals in the lowest to highest percentiles of polygenic risk, the probability of disease ranged from 17\% to 78\% for coronary artery disease; 13\% to 76\% for breast cancer; and 11\% to 80\% for colon cancer.Conclusions For three important genomic conditions, polygenic risk powerfully modifies the risk conferred by monogenic risk variants.Competing Interest StatementA.C.F. is a consultant and holds equity in GoodPath. A.P. is a Venture Partner at GV, a subsidiary of Alphabet Corporation. P.T.E. is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases, and has served on advisory boards or consulted for Bayer AG, Quest Diagnostics, and Novartis. S.K. is an employee of Verve Therapeutics, and holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics. He is a member of the scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; he has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, and Medscape; he reports patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). K.N. is an employee of IBM Research. A.V.K. has served as a consultant or received honoraria from Novartis Institute for Biomedical Research, Amarin Pharmaceuticals, Maze Therapeutics, Color Genomics, Illumina, and Navitor Pharmaceuticals, received grant support from the Novartis Institute for Biomedical Research and IBM Research, and reports a patent related to a genetic risk predictor (20190017119). J.R.H, C.L.N., C.L., and A.Y.Z. are employees of Color Genomics. E.S.L. serves on the Board of Directors for Codiak BioSciences and Neon Therapeutics; serves on the Scientific Advisory Board of F-Prime Capital Partners and Third Rock Ventures; serves on the Board of Directors of the Innocence Project, Count Me In, and Biden Cancer Initiative; and serves on the Board of Trustees for the Parker Institute for Cancer Immunotherapy. The remaining authors have no disclosures. Funding StatementFunding support was provided by grant T32HL007208 from the National Heart, Lung, and Blood Institute (A.P.P. and A.C.F.), grant 14CVD01 Fondation Leducq (P.T.E.), grants 1RO1HL092577, R01HL128914, K24HL105780 from the National Heart, Lung, and Blood Institute (P.T.E), grant 18SFRN34110082 from the American Heart Association (P.T.E.), an institutional grant from the Broad Institute of MIT and Harvard (BroadIgnite, to A.V.K.), grant 1K08HG010155 (to A.V.K.) and R01HG010372 (to C.A.C. and M.L.) from the National Human Genome Research Institute, a Hassenfeld Scholar Award from Massachusetts General Hospital (to A.V.K.), and a sponsored research agreement from IBM Research (to A.P., A.V.K.).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData on UK biobank participants is available to approved investigators directly form the UK biobank.}, URL = {https://www.medrxiv.org/content/early/2019/11/29/19013086}, eprint = {https://www.medrxiv.org/content/early/2019/11/29/19013086.full.pdf}, journal = {medRxiv} }